Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam R Glassman

Showing results (51-60 of 127) with videos related to

Pageof 13
Sort By:
Retina (Philadelphia, Pa.)|June 3, 2015
RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPYSusan B Bressler, Michele Melia, Adam R Glassman, et al.
Retina (Philadelphia, Pa.)|March 28, 2022
ASSESSMENT OF FLUORESCEIN ANGIOGRAPHY NONPERFUSION IN EYES WITH DIABETIC RETINOPATHY USING ULTRAWIDE FIELD RETINAL IMAGINGPaolo S Silva, Danni Liu, Adam R Glassman, et al.
JAMA Ophthalmology|May 12, 2017
Interim Safety Data Comparing Ranibizumab With Panretinal Photocoagulation Among Participants With Proliferative Diabetic RetinopathyJeffrey G Gross, Adam R Glassman, Margaret J Klein, et al.
Ophthalmology|October 16, 2010
Visual acuity testing using autorefraction or pinhole occluder compared with a manual protocol refraction in individuals with diabetesJennifer K Sun, Lloyd Paul Aiello, Jerry D Cavallerano, et al.
Ophthalmology|July 8, 2018
Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema OutcomesSusan B Bressler, Wesley T Beaulieu, Adam R Glassman, et al.
Ophthalmology|December 3, 2014
Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial resultsMichael J Elman, Allison Ayala, Neil M Bressler, et al.
Retina (Philadelphia, Pa.)|February 27, 2019
PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Should Baseline Characteristics Affect Choice of Treatment?Susan B Bressler, Wesley T Beaulieu, Adam R Glassman, et al.
JAMA Ophthalmology|October 21, 2021
Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical TrialMaureen G Maguire, Danni Liu, Susan B Bressler, et al.
American Journal of Ophthalmology|August 16, 2016
Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical TrialWesley T Beaulieu, Neil M Bressler, Michele Melia, et al.
JAMA Ophthalmology|June 28, 2019
Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical TrialNeil M Bressler, Isoken Odia, Maureen Maguire, et al.
Pageof 13

Showing results (51-60 of 127) with videos related to

Sort By:
Pageof 13
Retina (Philadelphia, Pa.)|June 3, 2015
RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPYSusan B Bressler, Michele Melia, Adam R Glassman, et al.
Retina (Philadelphia, Pa.)|March 28, 2022
ASSESSMENT OF FLUORESCEIN ANGIOGRAPHY NONPERFUSION IN EYES WITH DIABETIC RETINOPATHY USING ULTRAWIDE FIELD RETINAL IMAGINGPaolo S Silva, Danni Liu, Adam R Glassman, et al.
JAMA Ophthalmology|May 12, 2017
Interim Safety Data Comparing Ranibizumab With Panretinal Photocoagulation Among Participants With Proliferative Diabetic RetinopathyJeffrey G Gross, Adam R Glassman, Margaret J Klein, et al.
Ophthalmology|October 16, 2010
Visual acuity testing using autorefraction or pinhole occluder compared with a manual protocol refraction in individuals with diabetesJennifer K Sun, Lloyd Paul Aiello, Jerry D Cavallerano, et al.
Ophthalmology|July 8, 2018
Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema OutcomesSusan B Bressler, Wesley T Beaulieu, Adam R Glassman, et al.
Ophthalmology|December 3, 2014
Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial resultsMichael J Elman, Allison Ayala, Neil M Bressler, et al.
Retina (Philadelphia, Pa.)|February 27, 2019
PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Should Baseline Characteristics Affect Choice of Treatment?Susan B Bressler, Wesley T Beaulieu, Adam R Glassman, et al.
JAMA Ophthalmology|October 21, 2021
Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical TrialMaureen G Maguire, Danni Liu, Susan B Bressler, et al.
American Journal of Ophthalmology|August 16, 2016
Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical TrialWesley T Beaulieu, Neil M Bressler, Michele Melia, et al.
JAMA Ophthalmology|June 28, 2019
Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical TrialNeil M Bressler, Isoken Odia, Maureen Maguire, et al.
Pageof 13